Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?
Zacks Investment Research | Jul 13, 2017 04:38AM ET
On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (NASDAQ:IMGN) .
ImmunoGen is a development-stage biotechnology company focused on developing targeted cancer therapeutics, using its proprietary antibody-drug conjugate (ADC) technology.
The company’s shares have significantly outperformed the Zacks categorised Medical-Drugs industry so far this year, having soared 239.2%, while the industry has registered an increase of 6.3%.
ImmunoGen has made a significant progress with regard to the lead pipeline candidate, mirvetuximab soravtansine, which is currently in a phase III study (FORWARD I) as a single-agent therapy. It has been put on trial for treating patients with platinum-resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens.
Combination regimens with mirvetuximab soravtansine in ovarian cancer are in the phase Ib/II FORWARD II study, aiming to expand the eligible patient population. Following successful completion of dose escalation, a phase II expansion cohort in combination with Roche’s Avastin is also ongoing. ImmunoGen expects to report initial data from the FORWARD II study soon.
Notably, mirvetuximab soravtansine enjoys Orphan Drug status in both the U.S. and the EU for treatment of ovarian cancer.
Although the platinum-resistant ovarian cancer market provides an immense commercial potential, ImmunoGen is set to face intense competition, upon approval. Nonetheless, mirvetuximab soravtansine looks promising at this juncture and its sanction will be a huge boost to the company.
Apart from mirvetuximab soravtansine, ImmunoGen is working on developing a couple of other candidates, including IMGN779 and IMGN632. IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia with data expected later this year. The company plans to file an investigational new drug application (INDA) for IMGN632 to treat hematological malignancies in the third quarter of 2017.
ImmunoGen has agreements with several big healthcare companies including Amgen Inc. (NASDAQ:AMGN) , Bayer (DE:BAYGN), Eli Lilly and Company (NYSE:LLY) , Novartis (NYSE:NVS) , Roche, Sanofi (PA:SASY) and Takeda. These agreements in turn allow other companies to use ImmunoGen’s ADC technology and provide it with funds in the form of license and milestone fees, royalties, clinical materials revenue and R&D support fees.
Get The News You Want
ImmunoGen, Inc. Price and Consensus
ImmunoGen, Inc. Quote
Zacks Rank
ImmunoGencurrently carries a Zacks Rank #3 (Hold). You can see .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.